Lung Cancer

Alice T. Shaw, MD, PhD, and D. Ross Camidge, MD, PhD, discuss the evolution of ALK-targeting therapies, the impact on the drug development paradigm, and the prospects for future advancements.

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the CheckMate-227 trial in non–small cell lung cancer.

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

The European Commission has approved osimertinib (Tagrisso) as a frontline treatment for patients with EGFR-mutant locally-advanced or metastatic non–small cell lung cancer.

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses plasma EGFR mutations as a predictor of response to osimertinib (Tagrisso) in the AURA3 trial in non–small cell lung cancer.

Anne Chiang, MD, PhD, discusses recent developments with immunotherapy and the overall outlook for the treatment landscape of small cell lung cancer.

The combination of nivolumab and low-dose ipilimumab reduced the risk of progression or death by 52% compared with standard platinum doublet chemotherapy for patients with metastatic PD-L1–negative, tumor mutation burden-high non–small cell lung cancer.

The combination of bevacizumab (Avastin) and erlotinib (Tarceva) is superior to erlotinib alone as upfront treatment for non–small cell lung cancer harboring EGFR mutations.

The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel educed the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non–small cell lung cancer.

Robert M. Jotte, MD, PhD, medical director and co-chair, USON Thoracic Committee, Rocky Mountain Cancer Centers, discusses the phase III findings of the IMpower131 trial, which looked at the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) in patients with advanced squamous non

Combining pegilodecakin with nivolumab or pembrolizumab induced an overall response rate of 41% in patients with advanced non–small cell lung cancer.

Adding pembrolizumab to frontline carboplatin/paclitaxel or nab-paclitaxel reduced the risk of death by 36% compared with chemotherapy alone in patients with metastatic squamous non–small cell lung cancer.

Patients with non-small cell lung cancer treated with frontline pembrolizuma lived 4 to 8 months longer than those who received standard of care chemotherapy.

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cancer Genome Atlas (CCGA) study in an interview with OncLive during the 2018 ASCO Annual Meeting.

Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.

Initial results from the Circulating Cell-Free Genome Atlas study strongly suggest that cell-free DNA tests can be used with a high degree of specificity to detect signs of early stage lung cancer.

The addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) delayed the risk of progression or death by 29% compared with chemotherapy alone for patients with advanced squamous NSCLC.

The highly-selective RET inhibitor LOXO-292 demonstrated robust clinical activity across RET-altered solid tumors, including in patients with brain metastases and the RET V804M gatekeeper mutation.